drugset / Trial / NCT05405309
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) patients with DDR deficiencies.
Timeline
- Start
- 2022-09-23
- Primary completion
- 2023-10-24
- Completion
- 2025-01-10
Outcome
Outcome not reported
Stopped: “This study was terminated due to sponsor de-activation of all programs associated with RP-3500 (camonsertib).”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camonsertib | Small molecule | 40 mg | — |
| Subject | Camonsertib | Small molecule | 50 mg | — |
| Subject | Camonsertib | Small molecule | 80 mg | — |
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 150 mg | Oral |